PreprintCited by 72Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

BIN1 recovers tauopathy-induced long-term memory deficits in mice and interacts with Tau through Thr 348 phosphorylation

Open access

Preprint — published as 10.1007/s00401-019-02017-9 · Paper page

Abstract

The bridging integrator 1 gene ( BIN1 ) is a major genetic risk factor for Alzheimer’s disease (AD). In this report, we investigated how BIN1-dependent pathophysiological processes might be associated with Tau. We first generated a cohort of control and transgenic mice either overexpressing human MAPT (Tg MAPT ) or both human MAPT and BIN1 (Tg MAPT ;Tg BIN1 ), which we followed-up from 3 to 15 months. In Tg MAPT ;Tg BIN1 mice short-term memory deficits appeared earlier than in Tg MAPT mice; however – unlike Tg MAPT mice – Tg MAPT ;Tg BIN1 mice did not exhibit any long-term or spatial memory deficits for at least 15 months. After sacrifice of the cohort at 18 months, immunohistochemistry revealed that BIN1 overexpression prevents both Tau mislocalization and somatic inclusion in the hippocampus, where an increase in BIN1-Tau interaction was also observed. We then sought mechanisms controlling the BIN1-Tau interaction. We developed a high-content screening approach to characterize modulators of the BIN1-Tau interaction in an agnostic way (1,126 compounds targeting multiple pathways), and we identified – among others – an inhibitor of Calcineurin, a Ser/Thr phosphatase. We determined that Calcineurin dephosphorylates BIN1 on a Cyclin-dependent kinase phosphorylation site at T348, promoting the open conformation of the neuronal BIN1 isoform. Phosphorylation of this site increases the availability of the BIN1 SH3 domain for Tau interaction, as demonstrated by nuclear magnetic resonance experiments and in primary neurons. Finally, we observed that the levels of the neuronal BIN1 isoform were decreased in AD brains, whereas phospho-BIN1(T348):BIN1 ratio was increased, suggesting a compensatory mechanism. In conclusion, our data support the idea that BIN1 modulates the AD risk through an intricate regulation of its interaction with Tau. Alteration in BIN1 expression or activity may disrupt this regulatory balance with Tau and have direct effects on learning and memory.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/462317

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 50

  1. 10.1016/j.jalz.2012.11.007 · DOI · Paper page
  2. 10.1016/j.tins.2014.08.004 · DOI
  3. 10.1126/science.1072994 · DOI · Paper page
  4. 10.1001/archpsyc.63.2.168 · DOI · Paper page
  5. 10.1038/ng.803 · DOI · Paper page
  6. 10.1038/ng.439 · DOI · Paper page
  7. 10.1038/ng.2802 · DOI · Paper page
  8. 2010, Deciphering genetic susceptibility to frontotemporal lobar dementia, Nat Genet, 42, 189, 10.1038/ng0310-189 · DOI
  9. 10.1038/mp.2016.59 · DOI · Paper page
  10. 10.1016/j.ajhg.2011.01.006 · DOI
  11. 10.1093/hmg/ddt478 · DOI · Paper page
  12. 10.1371/journal.pgen.1004606 · DOI · Paper page
  13. 2013, GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer’s disease, Neuron, 78, 256, 10.1016/j.neuron.2013.02.026 · DOI · Paper page
  14. 10.1097/NEN.0b013e31825018f7 · DOI · Paper page
  15. 2018, Cognitive Decline in Preclinical Alzheimer’s Disease: Amyloid-Beta versus Tauopathy, J Alzheimers Dis, 61, 265
  16. 10.1038/mp.2013.1 · DOI · Paper page
  17. 10.1007/s00109-014-1138-1 · DOI · Paper page
  18. 10.1083/jcb.137.6.1355 · DOI · Paper page
  19. 10.1074/jbc.272.26.16700 · DOI · Paper page
  20. Daudin, R. , Marechal, D. , Wang, Q. et al. BIN1 genetic risk factor for Alzheimer is sufficient to induce early structural tract alterations in entorhinal cortex-dentate gyrus pathway and related hippocampal multi-scale impairments. bioRxiv (2018). · DOI · Paper page
  21. 10.1186/s13024-016-0124-1 · DOI · Paper page
  22. 10.1093/hmg/ddw146 · DOI · Paper page
  23. 2017, Multiscale network modeling of oligodendrocytes reveals molecular components of myelin dysregulation in Alzheimer’s disease, Mol Neurodegener, 12, 82, 10.1186/s13024-017-0219-3 · DOI · Paper page
  24. 10.1016/j.celrep.2016.09.063 · DOI · Paper page
  25. 10.1111/febs.14185 · DOI · Paper page
  26. 10.1523/JNEUROSCI.1065-09.2009 · DOI · Paper page
  27. 10.1046/j.1471-4159.2003.01879.x · DOI · Paper page
  28. 10.1523/JNEUROSCI.4637-04.2005 · DOI · Paper page
  29. 10.1016/S0165-0173(00)00019-9 · DOI
  30. 2015, Tau phosphorylation regulates the interaction between BIN1’s SH3 domain and Tau’s proline-rich domain, Acta Neuropathol Commun, 3, 58, 10.1186/s40478-015-0237-8 · DOI · Paper page
  31. 10.1074/jbc.272.49.30984 · DOI
  32. 10.1074/jbc.M008932200 · DOI
  33. Lasorsa, A. , Malki, I. , Cantrelle, F.X. et al. Structural basis of Tau interaction with BIN1 and regulation by Tau phosphorylation. Front Mol Neurosci 11, 421. · DOI · Paper page
  34. 10.1074/jbc.M115.700914 · DOI
  35. 10.1073/pnas.0406344101 · DOI · Paper page
  36. 10.1093/cercor/bhs033 · DOI · Paper page
  37. 2017, Genome-wide, high-content siRNA screening identifies the Alzheimer’s genetic risk factor FERMT2 as a major modulator of APP metabolism, Acta Neuropathol, 133, 955, 10.1007/s00401-016-1652-z · DOI · Paper page
  38. 10.1371/journal.pone.0078806 · DOI · Paper page
  39. 10.3233/JAD-132450 · DOI · Paper page
  40. 2018, Oligodendrogliopathy in neurodegenerative diseases with abnormal protein aggregates: The forgotten partner, Prog Neurobiol, 169, 24, 10.1016/j.pneurobio.2018.07.004 · DOI
  41. 10.1038/82868 · DOI · Paper page
  42. 10.1038/nprot.2012.099 · DOI
  43. 10.1038/nprot.2006.356 · DOI
  44. 2015, Analysis of autophagosome formation using lentiviral biosensors for live fluorescent cellular imaging, Methods Mol Biol, 1219, 157, 10.1007/978-1-4939-1661-0_12 · DOI
  45. 10.1007/s00401-006-0127-z · DOI · Paper page
  46. 2013, Elucidation of the BACE1 regulating factor GGA3 in Alzheimer’s disease, J Alzheimers Dis, 37, 217, 10.3233/JAD-130104 · DOI
  47. 2005, Methods for preparation of proteins and protein complexes that regulate the eukaryotic cell cycle for structural studies, Methods Mol Biol, 296, 219
  48. 10.1007/978-1-4939-2742-5_15 · DOI
  49. 10.1016/j.ymeth.2008.06.014 · DOI
  50. Gomes, I. , Sierra, S. & Devi, L.A. Detection of Receptor Heteromerization Using In Situ Proximity Ligation Assay. Curr Protoc Pharmacol 75, 2.16.11-12.16.31 (2016). · DOI

Cited by

Sorted by citations

Metadata

Authors
Sartori, M., Mendes, T., Desai, S., Lasorsa, A., Herledan, A., Malmanche, N., Mäkinen, P., Marttinen, M., Malki, I., Chapuis, J., Flaig, A., Vreulx, A.-C., Amouyel, P., Leroux, F., Déprez, B., Cantrelle, F.-X., Maréchal, D., Pradier, L., Hiltunen, M., Landrieu, I., Kilinc, D., Herault, Y., Laporte, J., & Lambert, J.-C.
Affiliations
  • Centre National de la Recherche Scientifique (FR)
  • Inserm (FR)
  • University of Eastern Finland (FI)
  • Sanofi (France) (FR)
Corresponding author
  • Laporte, Jocelyn
  • Lambert, Jean-Charles
Venue
Acta Neuropathologica
Publisher
openRxiv
Published
2018-11-07
Volume
138
Issue
4
Pages
631-652
ISSN
0001-6322 (ISSN-L)
OpenAlex
W2951997054
Cited by
72
References
1
Citations by year
2026: 8 · 2025: 9 · 2024: 8 · 2023: 7 · 2022: 12 · 2021: 11 · 2020: 9 · 2019: 7
FWCI
6.69
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Acta Neuropathologica (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
Funders
  • Alzheimer's Association (BFG-14-318355)
  • Sanofi
  • Itä-Suomen Yliopisto
  • EU Joint Programme – Neurodegenerative Disease Research (3DMiniBrain)
  • Fondation Vaincre Alzheimer
  • Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease
  • Université de Lille
  • Equipex
  • Agence Nationale de la Recherche (10 IDEX 0002, ANR-10-INBS-07, ANR-10-IDEX-0002, ANR-11-LABX-0009, 10-INBS-07694, ANR-10-LABX-0030, ANR-15-CE16-0002, ANR-10, ANR-10-LABX, ANR-10-INBS-0007, 15-CE-16-0002)
  • Institut National de la Santé et de la Recherche Médicale (ANR-10-INBS-07, ANR‐10‐LABX‐0030‐INRT)
  • Academy of Finland (307866)
  • Association Nationale de la Recherche et de la Technologie
  • Université de Strasbourg (10-IDEX-0002, ANR-10-LABX-0030, ANR-10-LABX-0030-INRT)
  • Centre National de la Recherche Scientifique (ANR-10-LABX-0030-INRT, FR‐3688)
  • Sigrid Juséliuksen Säätiö (307866)
  • Institute Pasteur De Lille
  • PHENOMIN (ANR-10-INBS-07)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
BIN1, tauopathy, Alzheimer's disease, tau phosphorylation, calcineurin, cyclin-dependent kinases, SH3 domain, long-term memory deficits, short-term memory impairment, hippocampus, transgenic mice, high-content screening
MeSH terms
Alzheimer Disease, Animals, Brain, Memory Disorders, Mice, Transgenic, Nerve Tissue Proteins, Neurons, Phosphorylation, tau Proteins, Tauopathies, Tumor Suppressor Proteins, Adaptor Proteins, Signal Transducing, Mice, Memory, Long-Term, Spatial Memory

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review